Amicus Therapeutics – Fabry Disease

Access Program Information

This program allows physicians to request permission from Amicus Therapeutics (Amicus) for
treatment access to migalastat hydrochloride (HCl) for specific adult patients with Fabry
disease. Treatment is open label for 6 months with renewal every 6 months.

Rare Disease: